Articles related to Oncology, Medical

Register now for the 2022 Virtual & In-Person CME Series, a multi-day, debate-driven, conference on neurotoxicity in hematologic cancers taking place from June 22-24.

Oral azactidine substantially improved survival compared with placebo irrespective of baseline MRD status, and the survival benefit with oral-AZA relative to placebo was greater in the baseline MRD+ subgroup than in the MRD− subgroup. Multivariate analysis confirmed the significant independent treatment effect of oral-AZA vs. placebo on OS and RFS when controlling for MRD status at baseline.

Perelman School of Medicine’s David Teachey, MD, reviews outcomes and implications from two recent Children’s Oncology Group trials and describes current research with daratumumab and CAR T-cell therapy.

Targeted therapy gene mutations may: (a) encode a protein that can be targeted in a manner distinct from the WT protein; (b) cause abnormal activation of a protein that is druggable but for which mutant-specific targeting has not been achieved; or (c) create novel molecular dependencies that are druggable. This article describe key examples of genetic drivers and associated modes of druggability, considers the clinical and research challenges in the field, and discusses new approaches to maximizing therapeutic benefit of targeted therapies.

The authors analyzed the immune cell infiltrates of head and neck squamous cell carcinoma and colorectal cancers and identified a subset of CD4 Th cells that appear to be directly involved in the anti-tumor immune response.

Despite the array of intensive treatment approaches, local control and overall survival rates in patients with advanced-stage disease remain low (approximately 40%–50% at 5 years). This review discusses recent studies integrating ICIs into definitive treatment regimens.